Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

Pfizer

Status and phase: Completed; Phase 2

Conditions: Attention Deficit Disorder With Hyperactivity

Treatments: Drug: Buspirone; Drug: Atomoxetine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00174226

A9001245

Details and patient eligibility

About

Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone

Enrollment: 241 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults with ADHD

Exclusion criteria

• Other Axis I Psychiatric Disorders

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind